Cabaletta Bio (CABA) Capital Leases (2024 - 2025)
Cabaletta Bio's quarterly Capital Leases came in at $2.9 million in Q4 2025, down 11.17% year-on-year from $3.2 million in Q4 2024, and down 36.84% quarter-over-quarter from $4.6 million in Q3 2025.
Cabaletta Bio has reported Capital Leases for 2 years, with the latest figure at $2.9 million in Q4 2025.
- For the quarter ending Q4 2025, Capital Leases fell 11.17% year-over-year to $2.9 million; the trailing twelve-month figure through Dec 2025 stood at $2.9 million (down 11.17% YoY), and the FY2025 full-year result was $2.9 million, down 11.17% from the prior year.
- Capital Leases for Q4 2025 stood at $2.9 million, down from $4.6 million in the prior quarter.
- The five-year high for Capital Leases was $8.1 million in Q1 2025, with the low at $2.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.88 Mn |
| Sep 30, 2025 | 4.56 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | 8.11 Mn |
| Dec 31, 2024 | 3.24 Mn |